Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
Breast Cancer Res 2018 Jan 19;20(1). Epub 2018 Jan 19.
Centre for Public Health, Queen's University Belfast, Belfast, UK.
Background: Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer development through increased prolactin levels and tamoxifen metabolism inhibition. Previous studies of breast cancer progression have focused on tamoxifen users, or have been limited by their small sample size and methodology. Read More